Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin

Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179–99.

Article  CAS  Google Scholar 

Bonasia CG, Abdulahad WH, Rutgers A, Heeringa P, Bos NA. B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells. Cells. 2021;10:1190.

Article  CAS  Google Scholar 

Genentech. RITUXAN (rituximab) [package insert]. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf

Sarsour K, Beckley-Kartey S, Melega S, Odueyungbo A, Kirchner P, Khalife N, et al. Rituximab utilization for approved and off-label nononcology indications and patients’ experiences with the patient alert card. Pharmacol Res Perspect. 2020;8: e00555.

Article  Google Scholar 

Gürcan HM, Keskin DB, Stern JNH, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9:10–25. Available at: https://www.sciencedirect.com/science/article/pii/S1567576908003196

Cobb P, Niederwieser D, Cohen S, Hamm C, Burmester G, Seo N, et al. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar. Immunotherapy. 2022;14:727–40.

Article  CAS  Google Scholar 

Deeks ED. CT-P10 (TruximaTM): a rituximab biosimilar. BioDrugs. 2017;31:275–8.

Article  CAS  Google Scholar 

Sharman JP, Liberati AM, Ishizawa K, Khan T, Robbins J, Alcasid A, et al. A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated cd20-positive, low-tumor-burden follicular lymphoma (LTB-FL). BioDrugs. 2020;34:171–81.

Article  CAS  Google Scholar 

Bag-Ozbek A, Hui-Yuen JS. Emerging B-cell therapies in systemic lupus erythematosus. Ther Clin Risk Manag. 2021;17:39–54.

Article  Google Scholar 

Furie R, Petri M, Zamani O. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2022;63:3918–30.

Article  Google Scholar 

Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol. 2020;21(1):149–56.

Article  Google Scholar 

Ahmed AR, Carrozzo M, Caux F. Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology. Exp Dermatol. 2016;25(11):839–46.

Article  CAS  Google Scholar 

Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol. 2019;44:740–6.

Article  CAS  Google Scholar 

Daneshvar E, Tavakolpour S, Mahmoudi H, Daneshpazhooh M, Teimourpour A, Aslani S, et al. Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents. Int J Dermatol. 2022. https://doi.org/10.1111/ijd.16363.

Article  Google Scholar 

Tavakolpour S, Mahmoudi H, Karami F, Elikaei Behjati S, Balighi K, Abbasi M, et al. Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatol Ther. 2020;33: e14380.

Article  CAS  Google Scholar 

Joly P, Maho-Vaillant M, Prost-Squarcioni C. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389:2031–40.

Article  CAS  Google Scholar 

Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384:2295–305.

Article  CAS  Google Scholar 

Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2022;47(5):785–8.

Article  Google Scholar 

Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–8.

Article  CAS  Google Scholar 

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.

Article  CAS  Google Scholar 

Joly P, Mouquet H, Roujeau J-C. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52.

Article  CAS  Google Scholar 

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166:405–12.

Article  Google Scholar 

Balighi K, Daneshpazhooh M, Khezri S, Mahdavi-nia M, Hajiseyed-javadi M, Chams-Davatchi C. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52:862–7.

Article  Google Scholar 

Loi C, Magnano M, Ravaioli GM, Sacchelli L, Patrizi A, Bardazzi F. Rituximab therapy in pemphigus: a long-term follow-up. Dermatol Ther. 2019;32(1): e12763.

Article  Google Scholar 

Wang H-H, Liu C-W, Li Y-C, Huang Y-C. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928–32.

Article  CAS  Google Scholar 

Kanwar AJ, Vinay K, Sawatkar GU. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170:1341–9.

Article  CAS  Google Scholar 

Iraji F, Danesh F, Faghihi G. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: a randomized clinical trial. Int Immunopharmacol. 2019;73:94–7.

Article  CAS  Google Scholar 

Kushner CJ, Wang S, Tovanabutra N, Tsai DE, Werth VP, Payne AS. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155:1404–9.

Article  Google Scholar 

Huang A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris: rituximab and beyond. J Am Acad Dermatol. 2016;74:746–53.

Article  CAS  Google Scholar 

Klufas DM, Amerson E, Twu O, Clark L, Shinkai K. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep. 2020;6:734–6.

Article  Google Scholar 

Rapp M, Pentland A, Richardson C. Successful treatment of pemphigus vulgaris with ofatumumab. J Drugs Dermatol. 2018;17(12):1338–9.

Google Scholar 

Novartis Pharmaceuticals. Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris. 2019. Available at http://clinicaltrials.gov

Ellebrecht CT, Choi EJ, Allman DM. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150:1331–5.

Article  Google Scholar 

Ruan J, Zhang X, Zheng M. Belimumab for the treatment of pemphigus. Dermatol Ther. 2022;35(8): e15621.

Article  CAS  Google Scholar 

Hall RP, Streilein RD, Hannah DL. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133:2786–8.

Article  CAS  Google Scholar 

Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: indications, optimized regimens, and practice gaps. Clin Dermatol. 2020;38:384–96.

Article  Google Scholar 

Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges. 2011;9(10):844–57.

Google Scholar 

Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. JDDG J der Dtsch Dermatologischen Gesellschaft. 2011;9:927–47.

Google Scholar 

Ronaghy A, Streilein RD, Hall RP. Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP). J Dermatol Sci. 2014;74(1):93–4.

Article  CAS  Google Scholar 

Tsai Y-J, Cho Y-T, Chu C-Y. Clinical effectiveness and safety of initial combination therapy with corticosteroids and rituximab in bullous pemphigoid: a retrospective cohort study. Am J Clin Dermatol. 2022;23:571–85.

Article  Google Scholar 

Cho YT, Chu CY, Wang LF. First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol. 2015;173:302–4.

Article  CAS  Google Scholar 

Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R. Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. J Am Acad Dermatol. 2019;81:179–86.

Article  CAS  Google Scholar 

Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016;74:700-8.e3.

Article  Google Scholar 

Yoo DS, Lee JH, Kim S-C, Kim JH. Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. Br J Dermatol. 2021;185:210–2.

Article  CAS  Google Scholar 

Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol. 2018;9:248–248.

Article  Google Scholar 

Silva N, Costa A, Salvador F, Serradeiro E. Bullous pemphigoid successfully treated with rituximab. Acta Med Port. 2022;30:243–6.

Article  Google Scholar 

Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2022;65:552–8.

Article  Google Scholar 

Wang T-S, Tsai T-F. Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate. Acta Derm Venereol. 2022;94:108–9.

Article  Google Scholar 

Xu H-H, Werth VP, Parisi E, Sollecito TP. Mucous membrane pemphigoid. Dent Clin North Am. 2013;57:611–30.

留言 (0)

沒有登入
gif